| Drug General Information |
| Drug ID |
D0R9VX
|
| Former ID |
DNCL003438
|
| Drug Name |
DS-3078
|
| Indication |
Solid cancer; Lymphoma [ICD9: 140-199, 140-229, 202.8; ICD10:C81-C86]
|
Phase 1 |
[1]
|
|---|
| Company |
Daiichi Sankyo
|
| Target and Pathway |
| Target(s) |
Serine/threonine-protein kinase mTOR |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
HIF-1 signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Hypoxia response via HIF activation
|
|
Interleukin signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
IL12-mediated signaling events
|
|
CDC42 signaling events
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
mTOR signaling pathway
|
|
CXCR4-mediated signaling events
|
|
EGFR-dependent Endothelin signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
CXCR3-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
PathWhiz Pathway
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Macroautophagy
|
|
mTORC1-mediated signalling
|
|
HSF1-dependent transactivation
|
|
CD28 dependent PI3K/Akt signaling
|
|
VEGFR2 mediated vascular permeability
|
|
TP53 Regulates Metabolic Genes
|
|
Constitutive Signaling by AKT1 E17K in Cancer
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Interferon type I signaling pathways
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
TSLP Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Signaling by Insulin receptor
|
|
Costimulation by the CD28 family
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
TOR Signaling
|
|
AMPK Signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01588678) A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health. |
|---|
| REF 2 | A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173. |
|---|
